- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02138188
Psychological Aspects and Insulin Pump Therapy
Psychological Aspects and Continuous Subcutaneous Insulin Infusion in Type 1 Diabetic Adults.
Study Overview
Status
Conditions
Detailed Description
The aim of this project is to study the psychological effect of Continuous Subcutaneous Insulin Infusion (CSII) in a cohort of type 1 diabetic patients and to explore the influence of psychological factors (coping style, locus of control, self-efficacy) on glycaemic control. A sample of 36 type 1 diabetic patients will be recruited at Endocrinology, Diabetes and Metabolism Division of Verona City Hospital.
Among T1DM patients routinely followed by our Institution the study will be proposed to those starting the CSII therapy based on the inclusion and exclusion criteria.
Each study participants will provide a written informed consent and will undergo a set of 4 psychological evaluation assessing depression, anxiety, self-efficacy, perceived interference caused by diabetes, family support, locus of control and coping strategies on top of routine medical examination and laboratory testing for outcome measures at baseline and after 6, 12 and 24 months after study entry.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
-
Verona, Italy, 37126
- Recruiting
- Division of Endocrinology, Diabetes and Metabolism-Department of Medicine-AOUI Verona
-
Contact:
- Maddalena Trombetta, MD Phd
- Phone Number: +39 045 8123110
- Email: maddalena.trombetta@univr.it
-
Principal Investigator:
- Maddalena Trombetta, MD Phd
-
Sub-Investigator:
- Liliana Indelicato, Psychologist
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Type 1 Diabetes
- Transition to CSII
- Age >18 years
Exclusion Criteria:
- Current schizophrenia/ psychotic disorders, bipolar disorders, addictive disorders, personality disorders
- Pregnancy
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
---|
T1D patients on CSII
Patients affected by Type 1 Diabetes on insulin pump therapy
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline glycosylated haemoglobin (HbA1c) at 6th, 12th and 24th months after transition to CSII.
Time Frame: Baseline, 6, 12 and 24 months
|
Glycosylated haemoglobin (HbA1c) is a lab test that shows the average level of blood glucose over the previous 3 months.
HbA1c is used in the present study as measure of the glycaemic control: it will be assessed at baseline, after 6, 12 and 24 months.
|
Baseline, 6, 12 and 24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline glucose variability as measured by standard deviation (SD) and coefficient of variation (CV) of capillary blood glucose test [mg/dL] at 6th, 12th and 24th months after transition to CSII.
Time Frame: Baseline, 6, 12, 24 months
|
SD and CV will be calculated from daily measurements of at least 3 capillary blood glucose measurements representative of pre- and post-meal glucose excursion over the entire day.
|
Baseline, 6, 12, 24 months
|
Change from baseline glucose variability as measured by the Low Blood Glucose Index (%LBGI) at 6th, 12th and 24th months after transition to CSII.
Time Frame: Baseline, 6, 12, 24 months
|
The LBGI is a validated percentage index of frequency and amplitude of glucose excursions below a conventional glucose threshold set at 6.25 mmol/L and allows the normalization of non-Gaussian distributions of both capillary and interstitial blood glucose measurements collected over a pre-determined time frame.
|
Baseline, 6, 12, 24 months
|
Change from baseline glucose variability as measured by High Blood Glucose Index (%HBGI) at 6th, 12th and 24th months after transition to CSII.
Time Frame: Baseline, 6, 12, 24 months
|
The HBGI is a validated percentage index of frequency and amplitude of glucose excursions over a conventional glucose threshold set at 6.25 mmol/L, as previously described.
|
Baseline, 6, 12, 24 months
|
Change from baseline depressive symptoms at 6th,12th and 24th months (BDI-II score)
Time Frame: Baseline, 6, 12, 24 months
|
The Beck Depression Inventory II is a 21-item questionnaire developed to assess the intensity of depression as defined by the Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition (DSM-IV). The BDI-II items include cognitive symptoms such as sadness and pessimism, affective symptoms such as loss of pleasure and loss of interest, somatic symptoms such as loss of energy, appetite changes and changes in sleep pattern. The BDI-II is calculated by summing the ratings for the 21 items. The 4-point scale ranges from 0 to 3 for each item. The maximum total score is 63. The measurement of outcome variables will be conducted 6, 12 and 24 months after transition to CSII. The difference of the BDI-II scores among baseline, at 6,12 and 24 months will be also calculated. |
Baseline, 6, 12, 24 months
|
Change from baseline anxiety symptoms at 6th,12th and 24th months (BAI score)
Time Frame: Baseline, 6, 12, 24 months
|
The Beck Anxiety Inventory is a 21- item questionnaire developed to assess the severity of anxiety by describing its emotional, physiological and cognitive symptoms.
The 4-point scale of BAI score ranges from 0 to 3 for each item, with a maximum total score of 63.
Outcome variables will be evaluated at 6, 12 and 24 months after transition to CSII.
The difference of the BAI scores among baseline, 6, 12 and 24 months will be also calculated.
|
Baseline, 6, 12, 24 months
|
Change from baseline general perceptions of diabetes at 6th, 12th and 24th months (MDQ Section 1 score)
Time Frame: Baseline, 6, 12, 24 months
|
The Multidimensional Diabetes Questionnaire (MDQ) was designed to provide a comprehensive assessment of diabetes-related cognitive and social factors. It includes 41 items subcategorized in three sections. The first section assesses the general perceptions of diabetes and related social support. It is comprised of three scales. These scales targets: perceived interference caused by diabetes to daily activities, work and social activities (9 items); perceived severity of diabetes (3 items); perceived diabetes-related social support from a significant other such as family, friends and health professionals (4 items). Responses were rated on 7-point rating scales (from 0 to 6), with higher scores indicating higher levels of perceived interference, social support and severity. |
Baseline, 6, 12, 24 months
|
Change from baseline family support at 6th, 12th and 24th months (MDQ section II score)
Time Frame: Baseline, 6, 12 and 24 months
|
This section of the MDQ measures social incentives in relation to self-care activities.
The scales included in this section were designed to measure the frequency of positive reinforcing behaviour (8 items) and the frequency of non supportive behaviours (4 items).
Subjects recorded their responses on 7-point Likert scales (from 0 to 6) with higher scores indicating higher levels of positive and negative reinforcement behaviours.
|
Baseline, 6, 12 and 24 months
|
Change from baseline Diabetes Self-Efficacy at 6th, 12th and 24th months (MDQ section III score)
Time Frame: Baseline, 6, 12, 24 months
|
This section of the MDQ is used to assess self-efficacy expectancies (7 items) and outcome expectancies (6 items).
The self-efficacy scale measured patients' confidence in their ability to perform behaviors specific to the diabetes self-care activities.
Responses were rated on a 0 to 100 rating scale.
The outcome expectancies scale assessed patients' perceptions of the effect of diabetes self-care behaviors on metabolic control.
Responses were rated on a 0 to 100 rating scale.
|
Baseline, 6, 12, 24 months
|
Determination of Health Locus of Control (MHLC) at Baseline
Time Frame: Baseline
|
The multidimensional Health Locus of Control Scale consists of three subscale with six items each.
The three subscales are: Internal Health Locus of Control (IHLC), Powerful Others Externality (PHLC), Chance Health Locus of Control (CHLC).
|
Baseline
|
Measures of Coping Strategies at Baseline
Time Frame: Baseline
|
Coping strategies will be measured with the Coping Orientation to Problems Experienced-New Italian Version (COPE-NVI).
The instrument is a multidimensional 60-items coping inventory to assess the different ways in which people respond to stress and it was developed to assess a broad range of coping responses.
|
Baseline
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Maddalena Trombetta, MD Phd, AOUI Verona
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ISP-DT1-ITA13 (CE-2393)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated